Publication

Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

Authors not recorded

Anticancer Res2011PMID 22199315stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerHigh-Grade Glioma, NOScivic_curation1.00
drugBevacizumabcivic_curation1.00
drugSunitinibcivic_curation1.00
geneIDH1civic_curation1.00
variantIDH1 R132civic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IDH1 R1325
Cetuximab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	submitted	EID3718 In a clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overal… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID4032 In a clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overal… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
(prognostic)	Glioma	Prognostic	B	Supports Better Outcome	3	submitted	EID4031 In a clinical study of 63 recurrent glioma patients, patients harboring IDH1 codon 132 mutation were associated with improved overall survival from initial diagnosis (56.5 vs. 21.3 months; P=0.001), a… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
Bevacizumab	High-Grade Glioma, NOS	Predictive	B	Supports Sensitivity Response	2	submitted	EID2330 In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival … (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
Bevacizumab + SunitinibSubstitutes	High-Grade Glioma, NOS	Predictive	B	Supports Sensitivity Response	2	accepted	EID2020 In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated wi… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
IDH1 R132S2
Cetuximab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	submitted	EID4033 In a clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overal… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
Bevacizumab	High-Grade Glioma, NOS	Predictive	B	Supports Sensitivity Response	2	submitted	EID2339 In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival … (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic